| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 27.646 | 13.665 | 13.438 | 14.602 | 45.366 | 30.857 | 73.836 | 32.671 | 35.400 | 35.207 |
| Total Income - EUR | 27.646 | 13.665 | 14.127 | 14.881 | 46.280 | 31.499 | 74.304 | 33.144 | 35.432 | 60.042 |
| Total Expenses - EUR | 5.566 | 5.334 | 8.868 | 5.535 | 20.182 | 24.408 | 31.538 | 41.875 | 52.249 | 55.799 |
| Gross Profit/Loss - EUR | 22.080 | 8.331 | 5.259 | 9.346 | 26.097 | 7.091 | 42.766 | -8.731 | -16.817 | 4.243 |
| Net Profit/Loss - EUR | 21.217 | 7.921 | 4.993 | 8.908 | 25.456 | 6.552 | 41.420 | -9.392 | -17.171 | 3.564 |
| Employees | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 |
Check the financial reports for the company - Osea-Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 1.614 | 1.072 | 547 | 3.902 | 8.780 | 7.191 | 10.188 | 18.148 | 18.892 |
| Current Assets | 42.463 | 50.497 | 54.236 | 64.885 | 78.161 | 69.436 | 100.475 | 50.643 | 32.397 | 51.303 |
| Inventories | 0 | 0 | 0 | 658 | 0 | 0 | 64 | 325 | 606 | 0 |
| Receivables | 23.613 | 17.009 | 21.302 | 18.121 | 17.068 | 16.226 | 23.256 | 21.454 | 22.136 | 25.382 |
| Cash | 18.850 | 33.489 | 32.934 | 46.106 | 61.093 | 53.209 | 77.155 | 28.864 | 9.654 | 25.921 |
| Shareholders Funds | 39.053 | 46.576 | 50.781 | 58.757 | 79.915 | 75.556 | 105.193 | 57.599 | 40.253 | 43.591 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.409 | 5.535 | 4.527 | 6.675 | 2.148 | 2.660 | 2.473 | 3.232 | 10.293 | 26.603 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7500 - 7500" | |||||||||
| CAEN Financial Year |
7500
|
|||||||||
Comments - Osea-Pharm Srl